1-6 of 6
Amanda Winters, MD PhD
Close
Sort by
Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Shanshan Pei, PhD, Daniel A Pollyea, MD, Annika Gustafson, Mohammad Minhajuddin, PhD, Brett M. Stevens, PhD, Haobin Ye, PhD, Anagha Inguva, BSc, Maria L Amaya, MD PhD, Anna Krug, BS, Courtney L Jones, PhD, Biniam Adane, PhD, Amanda Winters, MD PhD, Nabilah Khan, Jessica Ponder, PhD, Jeffrey Schowinsky, Andrew Hammes, MS, Diana Abbott, PhD, Jason R Myers, MS, John M Ashton, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Haley E. Ramsey, PhDMSc, Michael R. Savona, MD, Stephen W. Fesik, PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 185.
https://doi.org/10.1182/blood-2019-131390
Published: 2019
Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Amanda Winters, MD PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Brett M. Stevens, PhD, Shanshan Pei, PhD, Jeffrey Schowinsky, Diana Abbott, PhD, Andrew Hammes, MS, Molly Nakic, Lindsey Lyle, Keri Halsema, Dwight Macero, PA-C, Alex Hirose, Chelsey Boggs, Angie Falco, Natalie Monson, Shirstine Rahkola, Sarah Wright, Tyler D'Ovidio, Clayton Smith, MD, Craig T Jordan, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2638.
https://doi.org/10.1182/blood-2019-122120
Published: 2019
Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4615.
https://doi.org/10.1182/blood-2019-129150
Published: 2019
Journal Articles

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Amanda Winters, MD PhD, Madeline Goosman, Brett M Stevens, PhD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Daniel A Pollyea, MD, Craig T Jordan, PhD, Jonathan A Gutman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2138.
https://doi.org/10.1182/blood-2018-99-110834
Published: 2018
Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1337.
https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337
Published: 2017
Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 181.
https://doi.org/10.1182/blood.V130.Suppl_1.181.181
Published: 2017